Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900784 | 0.87 | GRM5 (0.56) | GRM5 | |
| SCHEMBL9904937 | 0.86 | GRM5 (0.57) | GRM5 | |
| SCHEMBL16682646 | 0.79 | PDCD1 (0.48) | PDCD1CD274 | |
| SCHEMBL16309565 | 0.76 | PDCD1 (0.45) | GRM5PDCD1CD274 | |
| SCHEMBL13836127 | 0.75 | GRM5 (0.51) | CYP1A2GRM5 | |
| SCHEMBL9904959 | 0.75 | GRM5 (0.51) | CYP1A2GRM5 | |
| SCHEMBL9904895 | 0.75 | GRM5 (0.51) | CYP1A2GRM5 | |
| SCHEMBL9938224 | 0.74 | CYP1A2 (0.64) | CYP1A2GRM5 | |
| SCHEMBL9926436 | 0.74 | GRM5 (0.50) | CYP1A2GRM5 | |
| SCHEMBL3548738 | 0.73 | PDCD1 (0.44) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255103-B2 | Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators | VANDERBILT UNIVERSITY (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255103-B2 | Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators | VANDERBILT UNIVERSITY (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2014-07-31 | — | — | US | disclosed |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2014-07-31 | — | — | US | disclosed |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2014-07-31 | — | — | US | disclosed |
| US-8703946-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703946-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703946-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2648723-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2012-11-22 | — | — | US | disclosed |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2012-11-22 | — | — | US | disclosed |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2012-11-22 | — | — | US | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | CYP1A2 3437/4885GRM5 1/4885PDCD1 2438/4885 |
| US-20120295913-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | CYP1A2 3437/4885GRM5 1/4885PDCD1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.